Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$73.22 USD

73.22
410,616

-0.74 (-1.00%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $73.21 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (185 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

DexCom's (DXCM) Q4 Earnings Beat, International Revenues Up

DexCom's (DXCM) fourth-quarter 2018 results benefit from strong contributions from the Sensor, Transmitter and Receiver segments.

Chemed (CHE) Q4 Earnings Beat Estimates, Gross Margin Falls

Chemed's (CHE) Q4 revenues grow across key segments.

Allscripts (MDRX) Q4 Earnings Lag Estimates, Bookings Up Y/Y

Significant year-over-year rise in bookings favors Allscripts' (MDRX) fourth-quarter 2018 results.

Integer Holdings' (ITGR) Q4 Earnings Beat, '19 View Strong

Integer Holdings (ITGR) gains from the core Medical Sales segment's impressive performance in fourth-quarter 2018.

NuVasive (NUVA) Q4 Earnings Beat Estimates, Margins Fall

NuVasive (NUVA) reports growth in revenues across all key operating segments in the fourth quarter of 2018.

Why Is Conmed (CNMD) Up 4.3% Since Last Earnings Report?

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Genomic Health (GHDX) Q4 Earnings Beat Estimates, Margins Up

Genomic Health's (GHDX) year-over-year rise in revenues, driven by a solid uptick in the United States and internationally, makes us optimistic about the stock.

CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up

CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition holds immense promise.

Henry Schein's (HSIC) Q4 Earnings Top, Revenues Lag Estimates

Strength in Henry Schein's (HSIC) global Medical and Technology and Value-added Services businesses in Q4 is encouraging.

Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down

Medtronic (MDT) demonstrates improved performances at CER based on growth in most of the business segments and all geographies.

Ecolab (ECL) Earnings and Revenues Match Estimates in Q4

Ecolab (ECL) sees solid segmental gains in Q4.

Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4

Cryolife (CRY) revenues increase year over year across all geographies and major segments.

Quidel (QDEL) Q4 Earnings and Revenues Surpass Estimates

Quidel's (QDEL) flagship Triage sees strong growth in China in Q4.

Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down

In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.

Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines

Bio-Techne (TECH) sees increase in revenues across key segments.

Here's Why Investors Should Buy CONMED (CNMD) Stock Now

CONMED's (CNMD) guidance for 2019 buoys optimism in the stock.

DaVita (DVA) Q4 Earnings Beat and Revenues Miss Estimates

DaVita's (DVA) Q4 results gain from increasing dialysis services in and outside the United States.

Medidata (MDSO) Q4 Earnings Beat, Revenues Miss Estimates

Medidata (MDSO) gains from solid segmental performance in Q4.

Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong

Bruker (BRKR) witnesses a sturdy organic revenue uptick riding on the strength of Bruker Scientific Instruments (BSI) and BEST segments.

STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates

STERIS (STE) continues to gain from strength in all business segments in Q3.

IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up

IRADIMED (IRMD) reports growth across all operating segments and geographies

Phirbo (PAHC) Q2 Earnings Lag Estimates, Operating Margin Up

Phirbo (PAHC) witnesses significant growth in core segment revenues in Q2.

Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss

Omnicell (OMCL) steadily benefits from product introductions, strategic alliances and digital conversions.

Cardinal Health (CAH) Surges: Stock Moves 6.8% Higher

Cardinal Health (CAH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

LabCorp's (LH) Q4 Earnings and Revenues Surpass Estimates

LabCorp's (LH) Q4 earnings gain on strength in the Covance Drug Development business.